News

From our CEO

27 March 2024

Rohan Greenland The May 50K

I’ve just signed up to do my fourth May 50K, and this year, I’m again running for two very special people, my cousin Clare and my niece’s partner Joseph. Clare has primary progressive MS and has enrolled in the OCTOPUS clinical trial in the UK, partnered with our PLATYPUS trial here in Australia.

(L-R): Rohan with his niece’s partner Joseph and cousin Claire.

While Clare was diagnosed with late-onset MS, Jo was diagnosed in his early 20s following the onset of problems with his vision. They motivate every step I take as I train for The May 50K and this year’s centrepiece, a Half Marathon in Canberra. Jo is also a runner, and with his MS well managed, likes to do Parkrun on Saturday mornings with my niece, Alice.

While many people with MS have significant levels of disability which prevents them from participating in running or walking activities, there is plenty of evidence – as the Cleveland Clinic advises – suggesting that exercise “decreases the severity of various MS symptoms, including fatigue and depressive symptoms, improves walking and balance, and enhances the quality of life”.

Jo can leave me in his dust, but that won’t deter me from lacing up, pestering all my friends and colleagues, and raising as much as I can to fuel the research that is taking us faster and further down the pathways to cures.

Please join me, and thousands of others, in what is a fabulous, fun and fundamentally important challenge.

Register for The May 50K.

Related News

MS News

Ocrevus and Kesimpta & the Government’s rapid review of MS medications

22 July 2026

On Thursday 16 July, the Australian Government announced that Ocrevus and Kesimpta would remain on the Pharmaceutical Benefits Scheme (PBS).

MS News

Thank you! Ocrevus and Kesimpta will remain on the PBS

17 July 2026

The Australian Government has confirmed that Ocrevus and Kesimpta will remain available through the Pharmaceutical Benefits Scheme (PBS), meaning thousands of Australians living with MS can continue to access these life-changing treatments. 

MS News

MS Australia applauds Health Minister’s announcement that Ocrevus and Kesimpta will remain on the PBS

16 July 2026

MS Australia warmly welcomes the announcement from the Minister for Health and Aged Care, the Hon Mark Butler MP, that Ocrevus (ocrelizumab) and Kesimpta (ofatumumab) will remain available through the Pharmaceutical Benefits Scheme (PBS).

Read More

Newsletter subscription

  • This field is for validation purposes and should be left unchanged.

From our CEO